Clinical Trial Update: Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis [NA]

View source ↗

Summary

This ClinicalTrials.gov update describes a study evaluating residual disease in resected non-small cell lung cancer using circulating tumor DNA analysis. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Nsclc | NA | Status: ACTIVE_NOT_RECRUITING